ResMed(RMD) ZACKS·2025-01-30 23:21分组1 - ResMed reported quarterly earnings of 2.30 per share, and up from 1.28 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.57%, and an increase from $1.16 billion year-over-year [2] - ResMed has consistently surpassed consensus EPS estimates and revenue estimates over the last four quarters [2] 分组2 - The stock has gained approximately 10.6% since the beginning of the year, outperforming the S&P 500's gain of 2.7% [3] - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at 9.35 for the current fiscal year [7] - The Zacks Industry Rank indicates that the Medical - Products sector is in the bottom 48% of over 250 Zacks industries, which may impact stock performance [8] 分组3 - The estimate revisions trend for ResMed is currently favorable, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting expected outperformance in the near future [6] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]